Dr. Rosenberg on Frontline Immunotherapy Potential in Bladder Cancer

Jonathan E. Rosenberg, MD
Published: Thursday, Jan 26, 2017



Jonathan E. Rosenberg, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential that immunotherapy has in the frontline setting for patients with bladder cancer.

For some patients, Rosenberg says immunotherapy is clearly going to be a first-choice therapy. However, researchers need to explore whether or not there are benefits to combining immunotherapy with chemotherapy. In many diseases, it hasn’t been beneficial.

However, in bladder cancer, there are chemotherapy regimens who do have high efficacy levels in patients. There may be some synergistic effects, which researchers will need to explore in multiple clinical trials.
 


Jonathan E. Rosenberg, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential that immunotherapy has in the frontline setting for patients with bladder cancer.

For some patients, Rosenberg says immunotherapy is clearly going to be a first-choice therapy. However, researchers need to explore whether or not there are benefits to combining immunotherapy with chemotherapy. In many diseases, it hasn’t been beneficial.

However, in bladder cancer, there are chemotherapy regimens who do have high efficacy levels in patients. There may be some synergistic effects, which researchers will need to explore in multiple clinical trials.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x